A new peg-filgrastim biosimilar, mecapegfilgrastim for primary prophylaxis of chemotherapy-related neutropenia is now available

Chemotherapy is still one of the main tools for treatment of pediatric and adult blood and solid tumors and is capable of cure some acute leukemia, some advanced lymphomas, advanced testicular cancers among others (1). However, the main side effects and limiting factors for its use is myelotoxicity, in particular neutropenia and eventual life threatening febrile neutropenia.